OLYMPUS LABS LAUNCHES PRE-ICO BRINGING A NEW FINANCIAL ECOSYSTEM TO THE BLOCKCHAIN WORLD
"Olympus Labs is an integrator of cryptocurrency-based financial products (e.g., indices, ETFs, options, futures, etc.). Olympus, third-party financial product developers, and Fintech applications build the products which include but are not limited to exchanges, market analytics tools, payment services, etc. (e.g., Kyber, Shapeshift, Sentiment)," explains Kai Chen, CEO of Olympus Labs.
On November 27, 2017 due to the high demand from outside investors Olympus Labs opened its doors for its Pre-ICO token sale.
The Olympus product is viable and has huge long-term potential. As for competition, it fills an evidently empty space in the cryptocurrency market, practically guaranteeing that Olympus' offerings will be used-and that this usage will generate profits. Olympus's mission is to "define the protocol for crypto-based derivatives," and it seems clear that these products will help mature the market beyond the current spot market.
The first of Olympus's products will allow one to borrow and lend bitcoin. Cryptocurrency index funds will be the second Olympus product to hit the market. These index funds will allow investors to buy into multiple cryptocurrencies at once, with profits moving with the market as a whole instead of with individual spot cryptocurrencies. Through customizable fintech-focused smart contracts, exchanges will be able to quickly and easily make their own indices which track the overall trend of cryptocurrencies traded on that exchange.
To Participate in the Pre-ICO
The Olympus Labs Token Sale started at 8 pm (GMT+8/UTC 12pm), 27 November 2017, and ends at 8pm (GMT+8/UTC 12 pm), 3 December 2017.Olympus Presale terms: Investors contributing more than 100 ETH, will get 10% bonus (1 ETH = 677 Olympus tokens). This will take place after ICO, and those who passed the KYC process, will be issued MOT, the rest who failed in KYC, will be refunded with ETH. For additional information and terms of the sale please visit the Olympus Labs website .
During the registration period (27 November 2017 to 3 December 2017), please visithttps://kyc.olympuslabs.io/ .
About OLYMPUS LABS
Olympus is led by a cohesive team with extensive expertise in both the traditional financial markets and blockchain technology. Olympus Founder and CEO Kai Chen started his career on Wall Street with Morgan Stanley, and he later went on to work for McKinsey and PIMCO. Our development team includes Google's former development community lead for China. On the business side, we have Danielle Sabrina, a highly sought-after marketing expert and veteran of several successful ICOs, and has helped her clients achieve prestigious awards such as Inc 500, Forbes Next Billion Dollar Startup, Entrepreneur 360 among other top level recognition. Danielle's work has also been featured in Huffington Post and Entrepreneur. Olympus also has a strong advising board made up of former executives at Morgan Stanley and McKinsey.
OLYMPUS LABS Social Media
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a88937da-05db-437e-92f0-07cc02b4dd8f
What Vibes Your Tribe
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
GlobeNewswire, Inc.26.5.2018 07:01 | pressemeddelelse
GlobeNewswire Test Release
Virgin Pulse25.5.2018 14:01 | pressemeddelelse
VIRGIN PULSE ANNOUNCES INDUSTRY-LEADING GDPR COMPLIANCE
Elemica24.5.2018 18:20 | pressemeddelelse
Elemica Reports Double Digit Network Growth and Announces New Product Innovations in First Quarter 2018
SNOMED International24.5.2018 15:17 | pressemeddelelse
Luxembourg Announced as SNOMED International's Newest Member
SEMAFO Inc.24.5.2018 14:02 | pressemeddelelse
SEMAFO Signs Underground Mining Services Contract with AUMS
Merus N.V.24.5.2018 13:01 | pressemeddelelse
Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum